Chicago’s Rush calls off merger with suburban hospital

The Rush hospital system based out of Chicago has ended plans to acquire Little Company of Mary of Evergreen Park, Illinois, which would’ve merged 12 facilities with Rush University Medical Center and its 2,500-student health sciences college.

According to the Chicago Tribune, Rush CEO Larry Goodman, MD, and president Michael Dandorph told employees in a memo that calling off the deal was mutual decision for Rush and Little Company of Mary.

“Though a difficult decision for both parties, we are confident that it is the right one,” the memo stated. “Both organizations maintain their mutual respect for each other and have decided to pursue efforts independently to advance care and service to Chicago area patients and communities.”

The deal had first been announced in October 2017. Little Company of Mary, with its 2,000 employees and 272-bed hospital in Evergreen Park, had been seeking an acquisition by a larger system since 2016 after taking on losses.

Rush had been looking to boost its presence in the Chicago suburbs to stay competitive in a consolidating market. Recently, Illinois’s largest health system, Advocate Health Care, finalized its merger with Milwaukee’s Aurora Health Care, creating the 10th largest nonprofit hospital system in the U.S.

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.